Cangrelor is a reversible, potent, competitive inhibitor of the ADP P2Y12 receptor, which is administered intravenously and rapidly achieves near-complete and predictable inhibition of ADP-induced platelet aggregation. In addition, cangrelor has a short half-life and thus a very fast offset of ...
Pregnancy and Lactation Heart attack(myocardialinfarction) is a medical emergency in pregnancy which can be fatal to pregnant woman and fetus if left untreated. Life-sustaining therapy for the pregnant woman should not be withheld due to potential concerns regarding the effects of the drug on the ...
Cangrelor, a powerful intravenous P2Y12 platelet receptor inhibitor, with immediate onset of action and a short half-life, is often employed in such cases; however, its safety in E-CPR remains unknown. METHODS. A retrospective analysis was performed on patients undergoing E-CPR for refractory ...
The short half-life of 3–6 min of can- grelor results in a rapid offset of antiplatelet effect and the effect on the bleeding time within 20 min after dis- continuation of the infusion. Its advantages over an oral P2Y12 inhibitor include more potent and rapid P2Y12 ...
The short half-life of 3–6 min of can- grelor results in a rapid offset of antiplatelet effect and the effect on the bleeding time within 20 min after dis- continuation of the infusion. Its advantages over an oral P2Y12 inhibitor include more potent and rapid P2Y12 ...
In particular, cangrelor given as a 30-μg/kg bolus followed by a 4-μg/kg/min infusion for 60 min to healthy adult volunteers resulted in a maximum concentration of 635 ng/ml, a drug half-life of 3.7 ± 1.1 min, and complete inhibition of ADP (5 μM)-induced platelet aggregation...
Cangrelor is a reversible, potent, competitive inhibitor of the ADP P2Y 12 receptor, which is administered intravenously and rapidly achieves near-complete and predictable inhibition of ADP-induced platelet aggregation. In addition, cangrelor has a short half-life and thus a very fast offset of ...
PurposeCangrelor is an intravenous P2Y12 receptor inhibitor with a rapid onset/offset of action and a short half-life (3–6 min). The objective was to present a preliminary experience regarding the safety and effectiveness using cangrelor, in combination with aspirin, in acute ischemic stroke ...
Cangrelor is an intravenous P2Y12receptor antagonist with a short half-life and rapid cessation of its effect after discontinuation. Three patients who presented to our emergency department with STEMI were started on cangrelor infusion prior to cardiac catheterization instead of other P2Y12receptor ...
An intravenous alternative, cangrelor, has rapid onset, short plasma half-life, and more reliable antiplatelet action for acute interventions. The study objective was to evaluate feasibility and safety of IV cangrelor during acute neuroendovascular surgery procedures. Methods We performed a retrospective ...